0001209191-20-015661.txt : 20200303
0001209191-20-015661.hdr.sgml : 20200303
20200303185712
ACCESSION NUMBER: 0001209191-20-015661
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200303
FILED AS OF DATE: 20200303
DATE AS OF CHANGE: 20200303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Woiwode Thomas
CENTRAL INDEX KEY: 0001619294
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39231
FILM NUMBER: 20684842
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Passage BIO, Inc.
CENTRAL INDEX KEY: 0001787297
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822729751
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: TWO COMMERCE SQUARE
STREET 2: 2001 MARKET STREET, 28TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
BUSINESS PHONE: 2678660312
MAIL ADDRESS:
STREET 1: TWO COMMERCE SQUARE
STREET 2: 2001 MARKET STREET, 28TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-03
0
0001787297
Passage BIO, Inc.
PASG
0001619294
Woiwode Thomas
ONE SANSOME STREET, SUITE 3630
SAN FRANCISCO
CA
94104
1
0
1
0
Common Stock
2020-03-03
4
C
0
2977242
A
2977242
I
By Versant Venture Capital VI, L.P.
Common Stock
2020-03-03
4
C
0
1049175
A
4026417
I
By Versant Venture Capital VI, L.P.
Common Stock
2020-03-03
4
C
0
708352
A
708352
I
By Versant Vantage I, L.P.
Common Stock
2020-03-03
4
P
0
225000
18.00
A
933352
I
By Versant Vantage I, L.P.
Series A-1 Preferred Stock
2020-03-03
4
C
0
2977242
0.00
D
Common Stock
2977242
0
I
By Versant Venture Capital VI, L.P.
Series A-2 Preferred Stock
2020-03-03
4
C
0
1049175
0.00
D
Common Stock
1049175
0
I
By Versant Venture Capital VI, L.P.
Series B Preferred Stock
2020-03-03
4
C
0
708352
0.00
D
Common Stock
708352
0
I
By Versant Vantage I, L.P.
Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020.
These securities are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
These securities are held of record by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
/s/ Richard Morris as attorney-in-fact for Thomas Woiwode
2020-03-03